A steroid derivative (RU 5135) exhibits epileptogenicity in the presence of deficient blood-brain barrier

Pro- and anticonvulsant effects of stress: the role of neuroactive steroids

The present review deals with findings related to the contribution of pro- and anticonvulsant effects of "neuroactive" steroids and the role of the gamma-aminobutyric acid (GABA) receptor as a physiological target for naturally occurring steroids. Ways are discussed via which GABAergic neurotransmission can be enhanced or reduced following maneuvers that inflict stress. The duality of stress effects is emphasized in conjunction with different types of epileptogenesis (e.g., grand mal vs petit mal) that undergo dissimilar evolution. Among the issues covered are steroid-induced sedation and epileptogenicity, excitatory steroids, stress and epilepsy, GABA and respiratory functions, asymmetric brain injury, and psychopathology and stress.

Epileptogenic activity in the amygdala is not affected by the amidine steroid, R 5135

The synthetic steroid amidine 3-alpha-hydroxy-16-imino-5-beta-17aza androstan-11-one (R 5135) is known to elicit long-lasting spiking in the cortex in the presence of neocortical damage. R 5135 administered to amygdaloid-kindled and naive rats resulted in regular, high-amplitude spiking in the cortex but only occasionally elicited small-amplitude spikes in the amygdala (AMY) and hippocampus (HPC). Interictal spikes from the AMY of kindled rats were not synchronized with cortical spikes induced by the steroid. Given that R 5135 is known to be a GABAA receptor antagonist, these findings suggest that GABAA receptors in AMY and HPC may have lower affinity for 3 alpha-hydroxysteroids.

The effects of systemic morphine on behavior and EEG in newborn rats

Early studies suggested that newborn animals are far more susceptible to the convulsant effect of systemic morphine than adult animals. The present study reassessed morphine's (0, 6, 12.5, 25, 50, 100 and 300 mg/kg) toxic effects, making use of electroencephalographic (EEG) recordings, behavioral observations and the specific opiate antagonist naloxone in immature rats (postnatal days 1, 3, 6, 12 and 24). Although morphine had opiate-specific effects (such as inhibition of activity at low doses), non-specific effects (such as hyperactivity) elicited by the highest doses, predominated in the 3 youngest age groups. At day 12 high doses of morphine first produced Straub tail and catatonia. At this age morphine produced EEG spikes that were not reversed by naloxone. Only at day 24 were electrographic spikes temporarily inhibited by naloxone. Behavioral convulsions were never observed, at any age. These findings indicate that morphine is less toxic in newborns than suggested previously.